Article
Medicine, General & Internal
Antonio Gidaro, Alessandro Palmerio Delitala, Alessandra Berzuini, Mark J. Soloski, Pietro Manca, Dante Castro, Emanuele Salvi, Roberto Manetti, Giorgio Lambertenghi Deliliers, Roberto Castelli
Summary: This study aimed to evaluate the effect of iron supplementation with ferric carboxymaltose (FCM) on the reduction of red blood cell transfusion rate in transfusion-dependent refractory anemia (RA) patients. The results showed that adding iron to ESAs can reduce RBCT requirement and improve hemoglobin levels.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Ameet Sarpatwari, Mengdong He, Frazer A. Tessema, Joshua J. Gagne, Aaron S. Kesselheim
Summary: The study evaluated the initiation of erythropoiesis stimulating agents (ESAs) darbepoetin alfa and epoetin alfa in cancer patients before and after implementation of a REMS program. The results showed that there were no significant changes in ESA initiation levels following the REMS program implementation and enforcement, raising concerns about the effectiveness of certain REMS programs in enhancing patient safety.
Article
Anesthesiology
Tom Friedman, Eldad J. Dann, Keren Bitton-Worms, Maged Makhoul, Roi Glam, Anastasia Weis, Derrick Y. Tam, Gil Bolotin
Summary: This study aimed to evaluate the effects of administering preoperative i.v. ferric carboxymaltose on postoperative red cell transfusion requirements in patients without anaemia undergoing on-pump cardiac surgery. The results showed that treatment with ferric carboxymaltose significantly reduced the need for red cell transfusions and increased postoperative haemoglobin concentration.
BRITISH JOURNAL OF ANAESTHESIA
(2023)
Article
Allergy
Stephanie Stojanovic, Linda Graudins, Ar Kar Aung, Louise Grannell, Mark Hew, Celia Zubrinich
Summary: The study found that recommencement of the index infusion is safe for Fishbane symptoms or mild to moderate hypersensitivity reactions. Subsequent rechallenge to an alternative formulation, including in cases of severe hypersensitivity reactions (although based on limited numbers), was also well tolerated. Rechallenge to the same formulation could be considered if alternative formulations are not available.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Review
Medicine, General & Internal
Sarah Lucas, Mayur Garg
Summary: Iron deficiency is a common worldwide nutritional deficiency with significant health consequences. Total dose intravenous iron replacement is recommended for patients with severe iron deficiency, especially in the presence of anaemia or when oral iron is ineffective or not tolerated. Available intravenous iron formulations have generally demonstrated good safety profiles, but potential adverse effects such as skin staining, infusion-related reactions, and hypophosphatemia have been reported. Understanding the administration and safety profiles of different iron formulations can help with appropriate prescription, counseling, and management of adverse events in patients requiring intravenous iron.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Urology & Nephrology
Miwa Masumoto, Takahiro Kuragano, Chisa Takata, Risako Fukui, Yuki Mihara, Rina Okamoto, Takahide Iwasaki, Satoshi Ookawa, Makoto Aichi, Mana Yahiro, Arithoshi Kida, Masayshi Nanami
Summary: The study found that treatment with long-acting ESA can reduce iron utilization, maintain target hemoglobin levels, without requiring a higher dose of IV iron or ESA.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2022)
Article
Transplantation
Annabel Biruete, Corinne E. Metzger, Neal X. Chen, Elizabeth A. Swallow, Curtis Vrabec, Erica L. Clinkenbeard, Alexander J. Stacy, Shruthi Srinivasan, Kalisha O'Neill, Keith G. Avin, Matthew R. Allen, Sharon M. Moe
Summary: This study compared the effects of ferric citrate (FC) and intravenous iron sucrose in rats with moderate chronic kidney disease (CKD). The results showed that FC treatment improved phosphorus homeostasis, some iron-related parameters, and the production and cleavage of FGF23. However, neither iron treatment had a significant effect on cardiovascular calcification and bone.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Medicine, General & Internal
Hea Ree Park, Su Jung Choi, Eun Yeon Joo
Summary: This study retrospectively evaluated the effectiveness of repeated intravenous ferric carboxymaltose (FCM) treatment for restless legs syndrome (RLS) patients. The results showed that repeated IV FCM was an effective treatment for primary RLS and RLS associated with iron deficiency. Serum ferritin might not be a reliable factor to monitor the sustained effects of IV iron for RLS.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Urology & Nephrology
Cheng-Wen Yang, Mei-Chen Lin, Kai-Hsiang Shu, Kuei-Tung Tung, Wan-Chuan Tsai, Ju-Yeh Yang, Mei-Fen Pai, Hon-Yen Wu, Yen-Ling Chiu, Yu-Sen Peng, Shih-Ping Hsu, Shi-Heng Wang, Szu-Yu Pan
Summary: The study analyzed the association between ESA dose and mortality in 304 hemodialysis patients in Taiwan. It found that an extremely low dose of ESA (<15,000 U) was associated with increased mortality risk while a higher dose (25,001-43,000 U) showed no significant increase in mortality risk compared to a moderate dose (15,000-25,000 U). Further research is needed to confirm this association.
AMERICAN JOURNAL OF NEPHROLOGY
(2023)
Review
Medicine, Research & Experimental
John A. Glaspy, Myles Wolf, William E. Strauss
Summary: Some intravenous iron formulations can lead to severe hypophosphatemia, especially in patients treated with ferric carboxymaltose. The consequences of severe HPP are usually bone abnormalities. However, there are still uncertainties and limitations in the research on HPP.
ADVANCES IN THERAPY
(2021)
Article
Cell Biology
Chun-Hsing Liao, Hsu-Feng Lu, Hsin-Hui Huang, Yu Chen, Li-Hua Li, Yi-Tsung Lin, Tsuey-Ching Yang
Summary: This study focused on elucidating the ferric citrate acquisition system of S. maltophilia, revealing the involvement of FciTABC and FeoABI systems in ferric citrate acquisition.
JOURNAL OF BIOMEDICAL SCIENCE
(2022)
Article
Medicine, General & Internal
Seok Hui Kang, Bo Yeon Kim, Eun Jung Son, Gui Ok Kim, Jun Young Do
Summary: This study aimed to evaluate the difference in patient survival according to the type of erythropoiesis-stimulating agent (ESA) treatment in the Korean hemodialysis population. The study analyzed retrospective data from a national HD quality assessment program and claims in Korea. The results showed that the MR group had comparable or better patient survival than the EP and DP groups in the multivariate analysis. However, it was difficult to determine the exact factors leading to the better patient survival in the MR group.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Urology & Nephrology
Takeshi Nakanishi, Takahiro Kuragano
Summary: A randomized controlled trial showed that high-dose intravenous iron therapy was superior to low-dose therapy for hemodialysis patients. Iron has dual effects on erythropoiesis, enhancing differentiation directly but inhibiting it indirectly by stimulating hepcidin and oxidative stress.
CLINICAL KIDNEY JOURNAL
(2021)
Article
Urology & Nephrology
Mark R. Hanudel, Brian Czaya, Shirley Wong, Maxime Rappaport, Shweta Namjoshi, Kristine Chua, Grace Jung, Victoria Gabayan, Bo Qiao, Elizabeta Nemeth, Tomas Ganz
Summary: This study demonstrates the efficacy of ferric citrate in high hepcidin models and shows that enteral ferric citrate absorption is dependent on conventional enterocyte iron transport by ferroportin, with minimal paracellular absorption occurring in these models.
KIDNEY INTERNATIONAL
(2022)
Article
Oncology
Jingyong Tan, Sitong Du, Xueyan Zang, Kaiyue Ding, Yelena Ginzburg, Huiyong Chen
Summary: This study conducted a meta-analysis to evaluate the efficacy of iron supplementation combined with erythropoiesis-stimulating agents (ESA) in managing chemotherapy-induced anemia (CIA). The results demonstrated that the combination therapy was more effective in improving anemia compared to iron supplementation alone, regardless of whether oral or intravenous iron was used.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Deepak L. Bhatt, Michael Szarek, Bertram Pitt, Christopher P. Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia B. Lewis, Matthew C. Riddle, Silvio E. Inzucchi, Mikhail N. Kosiborod, David Z. I. Cherney, Jamie P. Dwyer, Benjamin M. Scirica, Clifford J. Bailey, Rafael Diaz, Kausik K. Ray, Jacob A. Udell, Renato D. Lopes, Pablo Lapuerta, P. Gabriel Steg
Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Clinical Neurology
Ilya M. Nasrallah, Sarah A. Gaussoin, Raymond Pomponio, Sudipto Dolui, Guray Erus, Clinton B. Wright, Lenore J. Launer, John A. Detre, David A. Wolk, Christos Davatzikos, Jeff D. Williamson, Nicholas M. Pajewski, R. Nick Bryan
Summary: This study evaluated the impact of intensive blood pressure control on AD-related brain biomarkers, finding a greater decrease in hippocampal volume in the intensive treatment group compared to standard treatment. However, there were no significant differences in other MRI biomarkers of AD between the two treatment groups.
Article
Urology & Nephrology
Manjula Kurella Tamura, Sarah Gaussoin, Nicholas M. Pajewski, Greg Zaharchuk, Barry Freedman, Stephen R. Rapp, Alexander P. Auchus, William E. Haley, Suzanne Oparil, Jessica Kendrick, Christianne L. Roumie, Srinivasan Beddhu, Alfred K. Cheung, Jeff D. Williamson, John A. Detre, Sudipto Dolui, R. Nick Bryan, Ilya M. Nasrallah
Summary: This study aimed to investigate the effects of intensive blood pressure control on cerebral perfusion and structure in individuals with and without chronic kidney disease (CKD). The findings suggest that intensive blood pressure treatment in adults with early kidney disease does not appear to have a detrimental effect on brain perfusion or structure.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2022)
Article
Endocrinology & Metabolism
Ofri Mosenzon, Stephen D. Wiviott, Hiddo J. L. Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Ingrid A. M. Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A. Johansson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P. H. Wilding, Marc S. Sabatine, Itamar Raz
Summary: In the DECLARE-TIMI 58 trial, dapagliflozin showed a positive impact on urinary albumin-to-creatinine ratio and renal-specific outcomes, improving across baseline UACR categories; indicating a potential role for SGLT2i in the primary prevention of diabetic kidney disease.
Article
Cardiac & Cardiovascular Systems
Zachary L. Cox, Bonnie Ann Sarrell, Mary Katherine Cella, Brent Tucker, Juan P. Arroyo, Kausik Umanath, William Tidwell, Andrew Guide, Jeffrey M. Testani, Julia B. Lewis, Jamie P. Dwyer
Summary: This study investigated the safety and efficacy of multinephron segment diuretic therapy (MSDT), which combines four diuretic classes, in acute heart failure patients with diuretic resistance. The results showed that MSDT increased diuresis without affecting serum chemistries or kidney function. This study provides evidence for further exploration of MSDT in acute heart failure and diuretic resistance.
JOURNAL OF CARDIAC FAILURE
(2022)
Article
Urology & Nephrology
Hiddo J. L. Heerspink, David Cherney, Douwe Postmus, Bergur Stefansson, Glenn M. Chertow, Jamie P. Dwyer, Tom Greene, Mikhail Kosiborod, Anna Maria Langkilde, John J. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjostrom, Robert D. Toto, David C. Wheeler
Summary: This analysis of DAPA-CKD found that dapagliflozin can reduce the risk of abrupt declines in kidney function in patients with CKD and substantial albuminuria.
KIDNEY INTERNATIONAL
(2022)
Article
Medicine, General & Internal
Kazem Rahimi, Zeinab Bidel, Milad Nazarzadeh, Emma Copland, Dexter Canoy, Malgorzata Wamil, Jeannette Majert, Richard J. McManus, John Chalmers, Barry R. Davis, Carl J. Pepine, Koon K. Teo
Summary: A meta-analysis of randomized controlled trials found that pharmacological blood pressure reduction can reduce the risk of cardiovascular events in the elderly, with no variation in relative risk reduction based on age and baseline blood pressure levels, and greater absolute risk reductions in older age groups.
Article
Cardiac & Cardiovascular Systems
Dexter Canoy, Emma Copland, Milad Nazarzadeh, Rema Ramakrishnan, Ana-Catarina Pinho-Gomes, Abdul Salam, Jamie P. Dwyer, Farshad Farzadfar, Johan Sundstrom, Mark Woodward, Barry R. Davis, Kazem Rahimi
Summary: This study conducted a meta-analysis of individual patient-level data from randomized clinical trials to investigate the long-term effects of antihypertensive drugs on blood pressure. The results showed that antihypertensive drugs were effective in lowering blood pressure, with maximal effect observed after 12 months and gradual attenuation over time. The findings suggest the need for appropriate treatment strategies to sustain long-term blood pressure reductions.
Article
Endocrinology & Metabolism
Milad Nazarzadeh, Zeinab Bidel, Dexter Canoy, Emma Copland, Derrick A. Bennett, Abbas Dehghan, George Davey Smith, Rury R. Holman, Mark Woodward, Ajay Gupta, Amanda I. Adler, Malgorzata Wamil, Naveed Sattar, William C. Cushman, Richard J. McManus, Koon Teo, Barry R. Davis, John Chalmers, Carl J. Pepine, Kazem Rahimi
Summary: This study aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiovascular events in individuals with and without type 2 diabetes. The results showed that a 5 mm Hg reduction in systolic blood pressure decreased the risk of major cardiovascular events in both groups, but the relative treatment effect was weaker in participants with type 2 diabetes. However, there was no substantial difference in absolute risk reductions between people with and without type 2 diabetes.
LANCET DIABETES & ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Mingyao Sun, Nicole Hines, Diego Scerbo, Jane Buchanan, Chaorong Wu, Patrick Ten Eyck, Diana Zepeda-Orozco, Eric B. Taylor, Diana Jalal
Summary: Circulating xanthine oxidase (XO) does not significantly contribute to vascular disease in patients with chronic kidney disease (CKD). Allopurinol, while affecting XO activity, also impacts other pathways, which requires further investigation.
Article
Endocrinology & Metabolism
Ofri Mosenzon, Itamar Raz, Stephen D. Wiviott, Meir Schechter, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Sabina A. Murphy, Thomas A. Zelniker, Anna Maria Langkilde, Ingrid A. M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, John P. H. Wilding, Darren K. McGuire, Deepak L. Bhatt, Lawrence A. Leiter, Avivit Cahn, Jamie P. Dwyer, Hiddo J. L. Heerspink, Marc S. Sabatine
Summary: Dapagliflozin mitigated kidney function decline in patients with T2D at high cardiovascular risk, including those with low KDIGO risk, suggesting a role of dapagliflozin in the early prevention of diabetic kidney disease.
Review
Cell Biology
Samuel N. Heyman, Itamar Raz, Jamie P. Dwyer, Roni Weinberg Sibony, Julia B. Lewis, Zaid Abassi
Summary: Albuminuria is a hallmark of diabetic nephropathy and its development is influenced by various factors. Controlling glomerular albumin leak is crucial for preventing progression of the disease. Early interventions and treatments should be initiated before the onset of microalbuminuria, and the inhibition of the renin-angiotensin axis or sodium-glucose co-transport can be beneficial.
Article
Medicine, Research & Experimental
Jamie P. Dwyer, Abiy Agiro, Pooja Desai, Yemisi Oluwatosin
Summary: This study aimed to evaluate the impact of adding SZC therapy on 3-month medical costs in patients who experienced hyperkalemia while receiving RAASi therapy. The results showed that in patients who continued RAASi therapy with SZC, hyperkalemia-related and all-cause medical costs were significantly reduced, demonstrating cost savings with maintaining RAASi therapy with SZC.
ADVANCES IN THERAPY
(2023)
Article
Health Care Sciences & Services
Abiy Agiro, Jamie P. Dwyer, Yemisi Oluwatosin, Pooja Desai
Summary: The purpose of this study was to evaluate the impact of long-term sodium zirconium cyclosilicate (SZC) therapy on medical costs in patients with hyperkalemia. The study demonstrated that long-term outpatient treatment with SZC was associated with significant cost savings compared to no SZC therapy in patients with hyperkalemia.
CLINICOECONOMICS AND OUTCOMES RESEARCH
(2023)
Article
Urology & Nephrology
Mohamad A. Kalot, Abdallah El Alayli, Mohammad Al Khatib, Nedaa Husainat, Kerri McGreal, Diana Jalal, Alan S. L. Yu, Reem A. Mustafa
Summary: A computable phenotype using ICD-9/10 codes can accurately identify most patients with ADPKD, with acceptable sensitivity and specificity for patients seen in nephrology clinics and those not seen in nephrology clinics.